We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial ( MCL2): prolonged remissions without survival plateau.
- Authors
Eskelund, Christian W.; Kolstad, Arne; Jerkeman, Mats; Räty, Riikka; Laurell, Anna; Eloranta, Sandra; Smedby, Karin E.; Husby, Simon; Pedersen, Lone B.; Andersen, Niels S.; Eriksson, Mikael; Kimby, Eva; Bentzen, Hans; Kuittinen, Outi; Lauritzsen, Grete F.; Nilsson‐Ehle, Herman; Ralfkiær, Elisabeth; Ehinger, Mats; Sundström, Christer; Delabie, Jan
- Abstract
In recent decades, the prognosis of Mantle Cell Lymphoma ( MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL2 regimen, developed by the Nordic Lymphoma Group. We here present the 15-year updated results of the Nordic MCL2 study after a median follow-up of 11·4 years: For all patients on an intent-to-treat basis, the median overall and progression-free survival was 12·7 and 8·5 years, respectively. The MCL International Prognostic Index ( MIPI), biological MIPI, including Ki67 expression ( MIPI-B) and the MIPI-B including mIR-18b expression ( MIPI-B-miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12 years, we still see an excess disease-related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.
- Subjects
MANTLE cell lymphoma; CANCER relapse; RITUXIMAB; STEM cell transplantation; CYTARABINE; PROGRESSION-free survival; THERAPEUTICS
- Publication
British Journal of Haematology, 2016, Vol 175, Issue 3, p410
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.14241